World's Best Scientists 2026 revealed!
Olivier Bouché

Olivier Bouché

D-Index & Metrics

Medicine

D-Index
86
Citations
46683
World Ranking
13856
National Ranking
447

Olivier Bouché publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Olivier Bouché sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 661 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Olivier Bouché D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Olivier Bouché sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Olivier Bouché is affiliated with CHU de Reims in France and has a substantial research output in the field of medicine, with a pronounced focus on oncology. Their work spans across oncology, pulmonary and respiratory medicine, surgery, cancer research, and pathology and forensic medicine.

The main topics of Bouché's research include colorectal cancer treatments and studies, gastric cancer management and outcomes, pancreatic and hepatic oncology research, colorectal and anal carcinomas, cancer genomics and diagnostics, gastrointestinal tumor research and treatment, and genetic factors in colorectal cancer.

Bouché has frequently published in a variety of academic venues, with notable publication counts in:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Digestive and Liver Disease
  • European Journal of Cancer
  • Cancers

Recent publications include:

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial (2021, The Lancet Oncology)
  • Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer (2022, JAMA Oncology)
  • Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. (2020, Journal of Clinical Oncology)
  • Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) (2020, European Journal of Cancer)
  • Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR) (2020, Digestive and Liver Disease)

Bouché collaborates regularly with a group of coauthors contributing frequently across various studies. Prominent coauthors include:

  • David Tougeron
  • Thierry Lecomte
  • Julien Taïeb
  • Thomas Aparicio
  • Côme Lepage

The interdisciplinary nature of Bouché's work integrates clinical oncology, surgical approaches, and cancer diagnostics aimed at improving outcomes in gastrointestinal cancers. Their presence in high-impact journals and collaboration with other researchers underscores a consistent involvement in advancing cancer research and clinical guidelines.

Best Publications

  • FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

    Thierry Conroy;Françoise Desseigne;Marc Ychou;Olivier Bouché

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

    Marc Ychou;Valérie Boige;Jean-Pierre Pignon;Thierry Conroy

  • Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

    Jean-Pierre Gérard;Thierry Conroy;Franck Bonnetain;Olivier Bouché

  • KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

    Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre

  • Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102

    Laurent Bedenne;Pierre Michel;Olivier Bouché;Chantal Milan

  • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

    Jaafar Bennouna;Javier Sastre;Dirk Arnold;Pia Österlund

  • Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial

    Pascal Hammel;Florence Huguet;Jean-Luc van Laethem;David Goldstein

  • Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

    Jean-Pierre Gérard;David Azria;Sophie Gourgou-Bourgade;Isabelle Martel-Laffay

  • Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

    B. Chauffert;F. Mornex;Franck Bonnetain;P. Rougier

  • Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

    Pierre Laurent-Puig;Anne Cayre;Gilles Manceau;Emmanuel Buc

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

    Thierry Conroy;Jean-François Bosset;Pierre-Luc Etienne;Emmanuel Rio

  • Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.

    Guillaume Portier;Dominique Elias;Olivier Bouche;Philippe Rougier

  • Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

    Emmanuel Mitry;Anthony L.A. Fields;Harry Bleiberg;Roberto Labianca

  • Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients

    Valerie Taly;Deniz Pekin;Deniz Pekin;Leonor Benhaim;Steve K. Kotsopoulos

  • Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

    Sophie Gourgou-Bourgade;Caroline Bascoul-Mollevi;Françoise Desseigne;Marc Ychou

  • Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

    Jean-Pierre Gérard;David Azria;Sophie Gourgou-Bourgade;Isabelle Martel-Lafay

  • Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

    Thierry Conroy;Marie-Pierre Galais;Jean-Luc Raoul;Olivier Bouché

  • Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen

    Thierry André;Mohamed A. Bensmaine;Christophe Louvet;Eric François

  • Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

    Josep Tabernero;Heinz Josef Lenz;Salvatore Siena;Alberto Sobrero

Frequent Co-Authors

Marc Ychou
Marc Ychou University of Montpellier
Thierry André
Thierry André Université Paris Cité
Julien Taieb
Julien Taieb Université Paris Cité
Michel Ducreux
Michel Ducreux Institut Gustave Roussy
Christophe Borg
Christophe Borg Centre Hospitalier Universitaire de Besançon
Valérie Boige
Valérie Boige Institut Gustave Roussy
Pierre Laurent-Puig
Pierre Laurent-Puig Université Paris Cité
François Ghiringhelli
François Ghiringhelli Centre Georges François Leclerc
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online medical degrees opens up a variety of flexible options for students at different stages of their healthcare careers. For registered nurses looking to advance their education without attending in-person clinicals, online rn to bsn programs without clinical requirements offer a way to earn a bachelor’s degree on your own schedule.

Nurses aiming to reach the highest levels of clinical practice should consider accelerated dnp programs, which fast-track their journey to a Doctor of Nursing Practice. These options appeal to professionals seeking a quick transition to advanced roles.

If you are searching for the most accessible paths to doctoral qualifications, dnp programs vary in length, format, and entry requirements, making it easier to find one that fits your background and goals.

Entry-level healthcare professionals can also benefit from lpn accelerated program options. These online courses allow students to enter the workforce quickly while maintaining the flexibility needed for personal commitments.

Best Scientists Citing Olivier Bouché

Trending Scientists

Recently Published Articles